Neurocrine Biosciences Stocks List Ranked for 2024

	Symbol	Grade	Name	% Change
	NBIX	C	Neurocrine Biosciences, Inc.	1.61
	SPRB	D	Spruce Biosciences, Inc.	3.20

Related Industries: Biotechnology

Symbol	Grade	Name	Weight
PBE	C	PowerShares Dynamic Biotech & Genome	4.0
MNTL	D	Tema Neuroscience and Mental Health ETF	3.76
IBRN	B	iShares Neuroscience and Healthcare ETF	3.46
FBT	A	First Trust Amex Biotech Index Fund	3.42
XBI	B	SPDR S&P Biotech ETF	2.43

Compare ETFs

Compare FBT to XBI Compare PBE to FBT Compare PBE to IBRN

Date	Stock	Title
Oct 31	NBIX	Neurocrine Biosciences Inc (NBIX) Q3 2024 Earnings Call Highlights: Strong Sales and Strategic ...
Oct 31	NBIX	Decoding Neurocrine Biosciences Inc (NBIX): A Strategic SWOT Insight
Oct 30	NBIX	Neurocrine Biosciences, Inc. (NBIX) Q3 2024 Earnings Call Transcript
Oct 30	NBIX	Neurocrine stock jumps 9% on strong Ingrezza sales, stock buyback
Oct 30	NBIX	Neurocrine (NBIX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Oct 30	NBIX	Neurocrine Biosciences, Inc. 2024 Q3 - Results - Earnings Call Presentation
Oct 30	NBIX	Neurocrine Biosciences (NBIX) Q3 Earnings Miss Estimates
Oct 30	NBIX	Neurocrine: Q3 Earnings Snapshot
Oct 30	NBIX	Neurocrine Biosciences bats Q3 revenue estimates, revises guidance
Oct 30	NBIX	Neurocrine Biosciences Reports Third Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance
Oct 29	NBIX	Neurocrine Biosciences Q3 2024 Earnings Preview
Oct 28	SPRB	Spruce Biosciences to Participate in the Guggenheim Securities Healthcare Innovation Conference

Neurocrine Biosciences: Neurocrine Biosciences is a publicly traded biopharmaceutical company founded in 1992. The company is headquartered in San Diego, California, and led by CEO Kevin Gorman. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD).The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids.